On Monday, Taysha Gene Therapies Inc (NASDAQ: TSHA) was -7.14% drop from the session before, before settling in for the closing price of $4.76. A 52-week range for TSHA has been $1.05 – $5.40.
A company in the Healthcare sector has dropped its sales by -63.99% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 2.78%. With a float of $222.28 million, this company’s outstanding shares have now reached $272.73 million.
Taysha Gene Therapies Inc (TSHA) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Taysha Gene Therapies Inc stocks. The insider ownership of Taysha Gene Therapies Inc is 18.52%, while institutional ownership is 87.01%. The most recent insider transaction that took place on Sep 22 ’25, was worth 30,479. Before that another transaction happened on Sep 10 ’25, when Company’s President and Head of R&D sold 200,000 for $3.23, making the entire transaction worth $646,000. This insider now owns 1,006,439 shares in total.
Taysha Gene Therapies Inc (TSHA) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.07 earnings per share (EPS) during the time that was better than consensus figure (set at -0.09) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.78% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.54% during the next five years compared to -63.99% drop over the previous five years of trading.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
You can see what Taysha Gene Therapies Inc (TSHA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 12.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 148.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.43 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Let’s dig in a bit further. During the last 5-days, its volume was 32.88 million. That was better than the volume of 3.83 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 77.85%.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 68.89%, which indicates a significant increase from 63.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.31 in the past 14 days, which was higher than the 0.20 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.06, while its 200-day Moving Average is $2.26. However, in the short run, Taysha Gene Therapies Inc’s stock first resistance to watch stands at $4.74. Second resistance stands at $5.06. The third major resistance level sits at $5.23. If the price goes on to break the first support level at $4.25, it is likely to go to the next support level at $4.08. The third support level lies at $3.76 if the price breaches the second support level.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
There are 272,795K outstanding shares of the company, which has a market capitalization of 1.21 billion. As of now, sales total 8,330 K while income totals -89,300 K. Its latest quarter income was 1,990 K while its last quarter net income were -26,880 K.
